Sugi Predict

Sugi Predict / Compounds / SCHEMBL277927

SCHEMBL277927

SCHEMBL277927

Cc1nccn1Cc1ccc(N)cc1

nearest known ligand 0.69

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.64
▸ L3MBTL1 Q9Y468 1/20 0.64
▸ CYP11B1 P15538 1/20 0.46
▸ CYP11B2 P19099 1/20 0.46
▸ TSHR P16473 1/20 0.45
▸ KCNH2 Q12809 4/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HTR6 P50406 1/20 0.44
▸ HTR1A P08908 1/20 0.43
▸ HTR2C P28335 1/20 0.43
▸ GRM2 Q14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31270697 0.91 LMNA (0.74) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL31729500 0.85 LMNA (0.68) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL169675 0.85 LMNA (0.68) LMNAL3MBTL1CYP11B1CYP11B2KCNH2
SCHEMBL2950629 0.84 LMNA (0.71) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL301107 0.84 LMNA (0.66) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL10022388 0.83 LMNA (0.65) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL17102309 0.82 LMNA (0.64) LMNAL3MBTL1CYP11B1CYP11B2KCNH2
SCHEMBL7807461 0.82 LMNA (0.64) LMNAL3MBTL1KCNH2ALDH1A1POLB
SCHEMBL11113913 0.82 LMNA (0.64) LMNAL3MBTL1CYP11B1CYP11B2KCNH2
SCHEMBL26789087 0.82 LMNA (0.64) LMNAL3MBTL1TSHRKCNH2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024126777-A1 HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2024-06-20 — — WO disclosed
WO-2024126777-A1 HETEROAROMATIC COMPOUNDS ASTRAZENECA AB (SE) 2024-06-20 — — WO disclosed
US-20230133132-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-05-04 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 — — US disclosed
US-10000482-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2018-06-19 — — US disclosed
US-9802937-B2 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-10-31 — — US disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 — — US disclosed
CN-103626742-B Bi-aryl meta-pyrimidine inhibitors of kinases 塔格根公司 2017-04-26 — — CN disclosed
US-9499535-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2016-11-22 — — US disclosed
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases TARGEGEN, INC. (US) 2009-11-19 — — US disclosed
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases IMPACT BIOMEDICINES, INC. 2009-11-05 — — US disclosed
US-7528143-B2 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2009-05-05 — — US disclosed
WO-2009055674-A1 PYRROLOPYRIMIDINE ALKYNYL COMPOUNDS AND METHODS OF MAKING AND USING SAME TARGEGEN INC. (US) 2009-04-30 — — WO disclosed
WO-2009049028-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS TARGEGEN INC. (US) 2009-04-16 — — WO disclosed
CN-101370792-A Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN INC (US) 2009-02-18 — — CN disclosed
EP-1951684-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES Targegen, Inc. (US) 2008-08-06 — — EP disclosed
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-11-08 — — US disclosed
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases TARGEGEN, INC. (US) 2007-08-16 — — US disclosed
WO-2007053452-A1 BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES TARGEGEN, INC. (US) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286789-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, LTK LMNA 4525/4885L3MBTL1 3158/4885CYP11B1 4119/4885
US-20070191405-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 LMNA 4817/4885L3MBTL1 2347/4885CYP11B1 3431/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK LMNA 3015/4885L3MBTL1 457/4885CYP11B1 2185/4885
US-20230133132-A1 NAMPT MODULATORS NAMPT, MC4R, SIRT1 LMNA 2810/4885L3MBTL1 4152/4885CYP11B1 966/4885
US-20070259904-A1 Bi-aryl meta-pyrimidine inhibitors of kinases JAK2, TYK2, JAK3 LMNA 4817/4885L3MBTL1 2347/4885CYP11B1 3431/4885
US-20090275582-A1 Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases JAK2, TYK2, JAK3 LMNA 4817/4885L3MBTL1 2347/4885CYP11B1 3431/4885
US-10000482-B2 Kinase inhibitors LRRK2, MYLK2, MYLK LMNA 3115/4885L3MBTL1 485/4885CYP11B1 2280/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK LMNA 3115/4885L3MBTL1 485/4885CYP11B1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.